Indian J Pharm Close
 

Table 15: Question 4 (v): Would you consider the combination of everolimus and exemestane among post‑menopausal patients with HR +ve/Her2 – ve breast cancer who have >3 visceral organs involved by metastatic disease?

Table 15: Question 4 (v): Would you consider the combination of everolimus and exemestane among post‑menopausal patients with HR +ve/Her2 –  ve breast cancer who have >3 visceral organs involved by metastatic disease?